Oral semaglutide (Rybelsus) already exists for diabetes but at lower doses than injectable versions. Higher-dose oral semaglutide for weight loss has shown promising results in trials and may receive approval. Other oral GLP-1 agonists (orforglipron, danuglipron) are in development and could be game-changers by eliminating the injection barrier entirely. Oral versions generally show somewhat less weight loss than injectable in head-to-head comparisons, but they're rapidly improving. This could significantly change the landscape for both prescription and gray-market use.